© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Key opinion leaders review clinical cases in HER2-positive breast cancer, focusing on treatment options and clinical trials impacting treatment selection.
April 30th 2021
Andrew Seidman, MD, reviews the case of a 45-year-old woman with HER2+ breast cancer, and the panel discusses initial treatment.
May 18th 2021
Experts in breast cancer management discuss the use of anthracycline and risk of the cardiac toxicities.
The panel of experts reviews the use dual HER2-targeted therapy in HER2+ breast cancer.
Ingrid Mayer, MD, MSCI, and panel share the benefits of subcutaneous HP instead of IV HP therapy, particularly for the patients’ quality of life.
Andrew Seidman, MD, follows the patient after TCHP therapy and discusses the risk of recurrence with the experts.
Experts in the management of breast cancer review some trials leading to the future of personalized treatment for HER2+ breast cancer.
May 27th 2021
Ingrid Mayer, MD, MSCI, presents the case of a patient with high-risk HR+/HER2+ breast cancer who develops recurrence after a long disease-free interval.
The panel of experts in breast cancer discuss treatment options when the cancer has metastasized.
Carey Anders, MD, and Andrew Seidman, MD, share their recommendations for HER2+ breast cancer recurrence within 12 months of HP.
June 3rd 2021
Experts in the management of breast cancer discuss the role of tucatinib in patients with brain metastases.